Predictors of Mortality among Hospitalized Patients in a Tertiary Care Center across Three COVID-19 Waves.

Q3 Medicine
Anupama S Kakade, Anushree A Chaudhari, Gargee Bahekar, Shilpa Nellikkal, Anurag Bahekar, Deepak Bahekar, Alka Bahekar, Jaya Yednurwar
{"title":"Predictors of Mortality among Hospitalized Patients in a Tertiary Care Center across Three COVID-19 Waves.","authors":"Anupama S Kakade, Anushree A Chaudhari, Gargee Bahekar, Shilpa Nellikkal, Anurag Bahekar, Deepak Bahekar, Alka Bahekar, Jaya Yednurwar","doi":"10.59556/japi.73.1066","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Several studies conducted across the globe have stated the most frequent risk factors linked to increased severity and death related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the huge impact SARS-CoV-2 had on India, there is a lack of adequate research on the epidemiology and predictors of mortality due to coronavirus disease 2019 (COVID-19). The study aims to assess the predictors of mortality among COVID-19 patients admitted to a tertiary healthcare hospital in central India across the first, second, and third COVID-19 waves.</p><p><strong>Materials and methods: </strong>This record-based cross-sectional study was conducted using secondary data of patients hospitalized with SARS-CoV-2 between September 2020 and October 2022 in a designated COVID-19 treatment center.</p><p><strong>Results: </strong>Data on 861 adult patients were analyzed. The mean age of the patients was 52.87 ± 14.21 years, with the majority of them being females (573, 66.6%). Results showed no significant difference between men and women infected with COVID-19. During the complete course of the pandemic age patients, a history of hypertension, cough, dyspnea, myalgia, loss of taste, loss of smell, computed tomography (CT) score, and invasive ventilation was significantly associated with mortality of COVID-19 patients. Among the COVID-19 approved pharmacotherapy, steroids significantly (<i>p</i>-value < 0.000<b>)</b> lowered the risk of mortality [adjusted odds ratio (aOR): 0.134; 95% confidence interval (CI): 0.071-0.255] in COVID-19 hospitalized patients.</p><p><strong>Conclusion: </strong>Various sociodemographic and clinical profile predictors were associated with COVID-19 infection among pharmacotherapies. Steroid use helped lower the risk of mortality associated with COVID-19. More studies will help us to understand the various characteristics of the SARS-CoV-2 virus more elaborately, so as to ensure the proper preparedness of the healthcare system for future COVID-19 impacts.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 9","pages":"59-64"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.73.1066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Several studies conducted across the globe have stated the most frequent risk factors linked to increased severity and death related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the huge impact SARS-CoV-2 had on India, there is a lack of adequate research on the epidemiology and predictors of mortality due to coronavirus disease 2019 (COVID-19). The study aims to assess the predictors of mortality among COVID-19 patients admitted to a tertiary healthcare hospital in central India across the first, second, and third COVID-19 waves.

Materials and methods: This record-based cross-sectional study was conducted using secondary data of patients hospitalized with SARS-CoV-2 between September 2020 and October 2022 in a designated COVID-19 treatment center.

Results: Data on 861 adult patients were analyzed. The mean age of the patients was 52.87 ± 14.21 years, with the majority of them being females (573, 66.6%). Results showed no significant difference between men and women infected with COVID-19. During the complete course of the pandemic age patients, a history of hypertension, cough, dyspnea, myalgia, loss of taste, loss of smell, computed tomography (CT) score, and invasive ventilation was significantly associated with mortality of COVID-19 patients. Among the COVID-19 approved pharmacotherapy, steroids significantly (p-value < 0.000) lowered the risk of mortality [adjusted odds ratio (aOR): 0.134; 95% confidence interval (CI): 0.071-0.255] in COVID-19 hospitalized patients.

Conclusion: Various sociodemographic and clinical profile predictors were associated with COVID-19 infection among pharmacotherapies. Steroid use helped lower the risk of mortality associated with COVID-19. More studies will help us to understand the various characteristics of the SARS-CoV-2 virus more elaborately, so as to ensure the proper preparedness of the healthcare system for future COVID-19 impacts.

三级医疗中心住院患者在三次COVID-19浪潮中的死亡率预测因素
背景:在全球范围内进行的几项研究表明,与严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的严重程度和死亡增加相关的最常见危险因素。尽管SARS-CoV-2对印度造成了巨大影响,但对2019年冠状病毒病(COVID-19)的流行病学和死亡率预测因素缺乏充分的研究。该研究旨在评估印度中部一家三级医疗医院在第一、第二和第三波COVID-19浪潮中入院的COVID-19患者死亡率的预测因素。材料和方法:本研究基于记录的横断面研究使用了2020年9月至2022年10月在指定的COVID-19治疗中心住院的SARS-CoV-2患者的二次数据。结果:对861例成人患者资料进行分析。患者平均年龄为52.87±14.21岁,以女性573例(66.6%)居多。结果显示,男性和女性感染COVID-19无显著差异。在大流行年龄患者的整个病程中,高血压、咳嗽、呼吸困难、肌痛、味觉丧失、嗅觉丧失、计算机断层扫描(CT)评分和有创通气史与COVID-19患者的死亡率显著相关。在COVID-19批准的药物治疗中,类固醇显著(p值< 0.000)降低了死亡风险[校正优势比(aOR): 0.134;95%可信区间(CI): 0.071 ~ 0.255]。结论:各种社会人口学和临床特征预测因素与药物治疗中COVID-19感染相关。使用类固醇有助于降低与COVID-19相关的死亡风险。更多的研究将有助于我们更详细地了解SARS-CoV-2病毒的各种特征,从而确保医疗系统为未来的COVID-19影响做好适当的准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
509
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信